
Sign up to save your podcasts
Or


The editors also review the evidence for ocrelizumab for relapsing MS and early primary progressive MS (https://dtb.bmj.com/content/56/7/80), and discuss the role of metformin in people with type 1 diabetes (https://dtb.bmj.com/content/56/7/78).
By BMJ Group4.8
44 ratings
The editors also review the evidence for ocrelizumab for relapsing MS and early primary progressive MS (https://dtb.bmj.com/content/56/7/80), and discuss the role of metformin in people with type 1 diabetes (https://dtb.bmj.com/content/56/7/78).

1,096 Listeners

892 Listeners

211 Listeners

2,109 Listeners

2,025 Listeners

35 Listeners

47 Listeners

89 Listeners

7 Listeners

5 Listeners

3 Listeners

1 Listeners

3 Listeners

9 Listeners

40 Listeners

14 Listeners

1 Listeners

51 Listeners

0 Listeners

6 Listeners

16 Listeners

15 Listeners

3 Listeners

23 Listeners

1,093 Listeners

23 Listeners

8 Listeners

16 Listeners

169 Listeners

3,051 Listeners

2,096 Listeners

856 Listeners

5 Listeners

0 Listeners